Factors associated with caregiver burden among pharmacotherapy-treated children/adolescents with ADHD in the caregiver Perspective on Pediatric ADHD survey in Europe. NEUROPSYCHIATRIC DISEASE AND TREATMENT.

Burdens related to work, social activity, family life, and parental worry/stress were experienced by the caregivers of children/adolescents with ADHD, despite using ADHD pharmacotherapy. Better understanding of clinical/treatment characteristics most associated with...

Lanzamiento Intuniv. SHIRE

Intuniv® está indicado para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH) en niños y adolescentes de 6 a 17 años cuando los estimulantes no son adecuados, no se toleran o han mostrado ser ineficaces. Intuniv® se debe utilizar como parte...

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment. NEUROPSYCHIATRIC DISEASE AND TREATMENT

Although there are no published studies that address the sequential efficacy of ADHD medication as their primary objective, such studies as the present one can be informative. Subgroup analyses in this study highlight the importance of considering the medication...